Aim: To describe blood-pressure target attainment, in-hospital cardiorenal prescribing, and recorded cardiovascular conditions across chronic kidney disease stages, including dialysis.

Methods: This single-centre, prospective, cross-sectional observational study included 130 adults with chronic kidney disease and at least one prespecified cardiovascular condition, admitted between January and July 2025 (88 not on dialysis; 42 on dialysis). Final systolic blood pressure below 120 mmHg (the Kidney Disease: Improving Global Outcomes target for people not on dialysis) and below 140 mmHg was compared by dialysis status and disease stage. Cross-sectional associations with recorded cardiovascular conditions were explored using Firth penalised-likelihood logistic regression.

Results: Final systolic pressure was below 120 mmHg in 33.1% of patients (non-dialysis 37.5% versus dialysis 23.8%; difference −13.7 percentage points, 95% confidence interval −28.4 to +3.8) and below 140 mmHg in 72.3% (80.7% ver sus 54.8%; adjusted odds ratio 0.32, 95% confidence interval 0.14–0.71). No patient received an angiotensin-converting enzyme inhibitor together with an angiotensin receptor blocker (0/130; 95% confidence interval 0.0–2.8%), and no sodium-glucose cotransporter-2 inhibitor was prescribed. Left ventricular hypertrophy was associated with arrhythmias. Associations of diabetes or smoking with myocardial infarction were imprecise, and smoking and peripheral artery dis ease showed complete separation. Dyslipidemia was inversely associated with composite cardiovascular events, which should not be read as protective.

Conclusion: Systolic pressure below 140 mmHg was recorded less often among dialysis patients, and neither dual renin-angiotensin-aldosterone system blockade nor inpatient sodium-glucose cotransporter-2 inhibitor use was observed. Findings are cross-sectional and hypothesis-generating.

KEYWORDS: Chronic Kidney Disease, Blood Pressure, Dialysis, Cardiovascular Disease, Cross-Sectional Study.